# To Assess the Effects of Valsartan on Albuminuria/Proteinuria in Hypertensive Patients With Type 2 Diabetes Mellitus

> **NCT00550095** · PHASE4 · COMPLETED · sponsor: **Novartis** · enrollment: 509 (actual)

## Conditions studied

- Microalbuminuria
- Proteinuria

## Interventions

- **DRUG:** valsartan

## Key facts

- **NCT ID:** NCT00550095
- **Lead sponsor:** Novartis
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-06
- **Primary completion:** 2009-11
- **Final completion:** 2009-11
- **Target enrollment:** 509 (ACTUAL)
- **Last updated:** 2017-02-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00550095

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00550095, "To Assess the Effects of Valsartan on Albuminuria/Proteinuria in Hypertensive Patients With Type 2 Diabetes Mellitus". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT00550095. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*